A Multi-center, Randomized, Double-blind, Placebo-parallel Controlled Trial for the Efficacy and Safety of Shenfuqiangxin Pills in the Treatment of Chronic Heart Failure(Heart-Kidney Yang Deficiency Syndrome)

INTERVENTION: Experimental group:shenfuqiangxin pills;Control group:placebo; CONDITION: Chronic Heart Failure PRIMARY OUTCOME: NT‐proBNP; SECONDARY OUTCOME: echocardiography;composite endpoint event;New York Heart Association classification of cardiac function;6‐minute walk test;Minnesota Heart Failure Quality of Life Questionnaire;TCM Syndrome Points; INCLUSION CRITERIA: 1. Meet the diagnostic criteria of chronic heart failure, and have a history of chronic heart failure for more than 3 months or clinical symptoms of heart failure for more than 3 months; 2. Chronic heart failure patients with heart‐kidney yang deficiency syndrome based on syndrome differentiation of TCM; 3. Aged 18‐80 years; 4. Echocardiography showed the left ventricular ejection fraction (LVEF) was < 40%; 5. The patients with II to IV degree of the cardiac function stardand of New York Heart Association; 6. Serum N‐terminal proBNP content =450pg/ml; 7. Those who received at least 2 weeks of standardized western medicine treatment with the optimal therapeutic dose; 8. Those who had not used traditional Chinese medicine for heart failure within 2 weeks before enrollment; 9. Those who participate in this clinical trial voluntarily, understand and sign the informed consent.